Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications

More on GLP-1 and incretin signalling

• Semaglutide may protect kidneys by reducing vascular resistance

  Nature Medicine · 4 Oct 2026

  

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• NMR metabolomics improves prediction of cardiometabolic diseases

  medRxiv · 4 Oct 2026

  

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026